Affinage

CLDN3

Claudin-3 · UniProt O15551

Round 2 corrected
Length
220 aa
Mass
23.3 kDa
Annotated
2026-04-28
51 papers in source corpus 18 papers cited in narrative 19 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CLDN3 is a barrier-forming tight junction protein that seals the paracellular pathway against ions of both charges and uncharged solutes by assembling into homo- and heteromeric strands with claudin-1 and claudin-2 (PMID:10562289, PMID:20655293). Its C-terminal YV motif recruits ZO-1, ZO-2, and ZO-3 via their PDZ1 domains, anchoring strands to the submembranous scaffold (PMID:10601346), and WNK4 kinase phosphorylates CLDN3 to modulate paracellular chloride permeability (PMID:15070779). Beyond its structural barrier role, CLDN3 serves as a functional receptor for Clostridium perfringens enterotoxin (PMID:9334247) and as an antiviral decoy whose EC1 loop binds rotavirus VP7 to block viral attachment (PMID:41860939), and it promotes MMP-2 activation and cell invasion when overexpressed in epithelial cancers (PMID:16103090, PMID:11382769).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 1997 High

    Establishing that CLDN3 is sufficient to confer sensitivity to Clostridium perfringens enterotoxin (CPE) identified it as a functional CPE receptor before its tight junction role was fully appreciated.

    Evidence Gain-of-function transfection of L929 cells with CLDN3 cDNA followed by CPE binding and cytolysis assays

    PMID:9334247

    Open questions at the time
    • Binding interface between CPE and CLDN3 not mapped
    • Whether CPE binding requires CLDN3 in assembled strands or monomers was unknown
  2. 1999 High

    Three concurrent studies established that CLDN3 is a bona fide tight junction strand component that forms heteromeric/heterophilic complexes with claudin-1 and claudin-2 and recruits ZO-1/ZO-2/ZO-3 through its C-terminal YV motif, defining the molecular architecture of claudin-based tight junctions.

    Evidence ImmunoEM in liver/kidney (PMID:9892664); co-transfection/co-culture/immunoEM in L fibroblasts (PMID:10562289); in vitro PDZ1 binding assay with mutagenesis (PMID:10601346)

    PMID:10562289 PMID:10601346 PMID:9892664

    Open questions at the time
    • Stoichiometry and structural basis of heteromeric strand assembly not resolved
    • Functional consequence of ZO-protein recruitment on barrier selectivity not tested
  3. 2001 Medium

    Discovery that CLDN3 stimulates MT-MMP-mediated pro-MMP-2 activation revealed an unexpected signaling role beyond passive barrier formation, linking tight junction proteins to extracellular matrix remodeling.

    Evidence Expression cloning in 293T cells, co-immunoprecipitation with MT1-MMP and MMP-2, pro-MMP-2 processing assay

    PMID:11382769

    Open questions at the time
    • Direct binding interface between CLDN3 and MT1-MMP uncharacterized
    • Whether CLDN3-MMP interaction occurs at tight junctions or elsewhere not determined
  4. 2004 High

    Identification of WNK4 as a kinase that directly phosphorylates CLDN3 and increases paracellular chloride permeability provided the first post-translational regulatory mechanism controlling CLDN3 barrier function.

    Evidence In vitro kinase assay, co-immunoprecipitation, transepithelial ion permeability in MDCK II cells expressing wild-type or mutant WNK4

    PMID:15070779

    Open questions at the time
    • Specific phosphorylation site(s) on CLDN3 not mapped
    • Whether phosphorylation alters strand assembly or ZO-protein interaction not determined
  5. 2005 High

    Reciprocal gain- and loss-of-function experiments established that CLDN3 promotes cell invasion and motility in ovarian cancer cells through MMP-2 activation, extending the MMP-2 connection into a disease-relevant cell biological phenotype.

    Evidence Stable transfection of HOSE cells, siRNA knockdown in ovarian cancer lines, Boyden chamber invasion, wound healing, MMP-2 zymography

    PMID:16103090

    Open questions at the time
    • Whether CLDN3-driven invasion depends on tight junction localization or mislocalized protein unclear
    • Downstream signaling intermediates not defined
  6. 2007 Medium

    Mapping the CLDN3 promoter revealed Sp1 as a critical transcription factor whose binding is methylation-sensitive, providing a mechanism for epigenetic silencing and derepression of CLDN3 in cancer.

    Evidence Promoter deletion analysis, ChIP, in vitro DNA binding, Sp1 siRNA knockdown, DNA methylation analysis

    PMID:17986852

    Open questions at the time
    • Whether Sp1-driven transcription is tissue-specific not addressed
    • Upstream signals controlling promoter methylation not identified
  7. 2010 High

    Comprehensive permeability profiling confirmed CLDN3 as a general sealing claudin that restricts both charged and uncharged solute flux without affecting water permeability, while reshaping strand morphology into continuous meshwork loops.

    Evidence Stable CLDN3 expression in MDCK II cells, multi-ion and tracer flux assays, freeze-fracture EM of strand architecture

    PMID:20655293

    Open questions at the time
    • Structural basis for non-charge-selective sealing not resolved at atomic level
    • Contribution of CLDN3 heteromeric strands versus homomeric strands not dissected
  8. 2010 Medium

    Epigenetic profiling showed that CLDN3 repression in normal ovarian epithelium depends on bivalent histone marks (H3K4me3 + H3K27me3), and derepression in tumors correlates with loss of H3K27me3 and H4K20me3, refining the chromatin-level regulation beyond DNA methylation alone.

    Evidence ChIP for histone modifications, bisulfite sequencing, DNA methyltransferase and HDAC inhibitor treatments in ovarian epithelial and cancer cells

    PMID:20053926

    Open questions at the time
    • Causal writers/erasers of H3K27me3 at CLDN3 locus not identified
    • Whether bivalent state exists in non-ovarian tissues unknown
  9. 2024 Medium

    Establishing the PPM1G→TET1→CLDN3 promoter demethylation axis showed how upstream phosphatase activity controls CLDN3 transcription through TET1 stability, linking CLDN3 expression to epithelial-mesenchymal transition in cholangiocarcinoma.

    Evidence ChIP, bisulfite sequencing, phosphatase activity assay, co-immunoprecipitation, protein stability assays in cholangiocarcinoma cells

    PMID:39477806

    Open questions at the time
    • Whether the PPM1G-TET1-CLDN3 axis operates in normal epithelia not tested
    • TET1 phosphorylation site affecting CLDN3 regulation not mapped
  10. 2025 High

    Identification of CLDN3 EC1 as a decoy receptor for rotavirus VP7 — with E74 on VP7 as a critical contact residue — revealed an innate antiviral function for a tight junction protein, where viral VP8* counter-displaces CLDN3 from the membrane.

    Evidence CRISPR knockout, RNAi, viral binding/entry assays, co-IP, structural analysis, E74K mutagenesis, in vivo mouse infection

    PMID:41860939

    Open questions at the time
    • Atomic-resolution structure of CLDN3-VP7 complex not available
    • Whether other claudin family members share antiviral activity against rotavirus not tested
  11. 2025 Medium

    HSF1 was identified as a direct transcriptional activator of CLDN3 in colorectal cancer, adding a stress-responsive transcription factor to the regulatory repertoire alongside Sp1 and TET1.

    Evidence ChIP assay for HSF1 at CLDN3 promoter, reciprocal knockdown/overexpression, in vivo xenograft

    PMID:40162508

    Open questions at the time
    • Whether heat shock or proteotoxic stress acutely induces CLDN3 through HSF1 not tested
    • Relationship between HSF1 and Sp1/TET1 pathways at the CLDN3 promoter not addressed
  12. 2025 Medium

    Discovery that TRIM28 mediates CLDN3 SUMOylation and subsequent degradation established a post-translational mechanism controlling CLDN3 protein stability, complementing the transcriptional and phosphorylation-based regulatory layers.

    Evidence Co-immunoprecipitation, SUMOylation Western blot, siRNA/overexpression in CRC cells

    PMID:41762617

    Open questions at the time
    • Specific SUMOylation site(s) on CLDN3 not mapped
    • Whether TRIM28-mediated degradation is proteasomal or lysosomal not determined
    • Single lab, awaits independent replication

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include the atomic structure of CLDN3 homo- and heteromeric strands, the identity of WNK4 phosphorylation sites that regulate barrier function, whether CLDN3's antiviral and MMP-activating roles are functionally separable from its tight junction barrier activity, and the in vivo relevance of CLDN3-mediated actomyosin regulation in mammalian neural tube closure.
  • No high-resolution structure of CLDN3 in strand context
  • Phosphorylation site mapping incomplete
  • In vivo mammalian loss-of-function phenotype not well characterized

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098631 cell adhesion mediator activity 4 GO:0005198 structural molecule activity 3 GO:0001618 virus receptor activity 1
Localization
GO:0005886 plasma membrane 3
Pathway
R-HSA-1500931 Cell-Cell communication 4 R-HSA-1643685 Disease 2 R-HSA-168256 Immune System 2
Partners
CLDN1CLDN2MMP14TJP1TJP2TJP3TRIM28WNK4
Complex memberships
Tight junction strand (claudin heteromeric complex)

Evidence

Reading pass · 19 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1999 Claudin-3 (identified as mouse RVP1 homolog) is a four-transmembrane domain protein that concentrates exclusively at tight junctions in liver and kidney, as demonstrated by immunofluorescence and immunoelectron microscopy, establishing it as a bona fide tight junction strand component. Immunofluorescence microscopy, immunoelectron microscopy, transfection into MDCK cells Proceedings of the National Academy of Sciences of the United States of America High 9892664
1999 ZO-1, ZO-2, and ZO-3 directly bind the COOH-terminal YV sequence of claudin-3 (and claudins 1-8) through their PDZ1 domains in vitro, and ZO-1 is recruited to claudin-based networks at cell-cell borders in fibroblasts transfected with claudins. In vitro binding assay, transfection into L fibroblasts, co-localization by immunofluorescence The Journal of cell biology High 10601346
1999 Claudin-3 can form heteromeric tight junction strands with claudin-1 and claudin-2, and claudin-3 strands can associate laterally with claudin-1 and claudin-2 strands in trans (heterophilic interactions), whereas claudin-1 and claudin-2 strands do not interact with each other. Co-transfection into L fibroblasts, co-culture experiments, immunoreplica electron microscopy The Journal of cell biology High 10562289
1997 Claudin-3 (then called the human RVP1 homolog) functions as a receptor for Clostridium perfringens enterotoxin (CPE): L929 cells transfected with claudin-3 cDNA became sensitive to CPE, demonstrating it is sufficient to mediate CPE binding and cytolysis. Transfection of L929 cells, CPE binding assay, cytotoxicity assay The Journal of biological chemistry High 9334247
2001 Claudin-3 promotes activation of pro-MMP-2 mediated by membrane-type MMPs (MT-MMPs): claudin-3 expression in 293T cells stimulated MT-MMP-mediated pro-MMP-2 processing, and direct interaction of claudin family members with MT1-MMP and MMP-2 was demonstrated by immunoprecipitation. Expression cloning, co-immunoprecipitation, pro-MMP-2 activation assay in 293T cells The Journal of biological chemistry Medium 11382769
2003 In human airways, claudin-3 contributes to tight junction barrier function: stable expression of claudin-3 in NIH/3T3 and IB3.1 airway cells decreased solute permeability, and co-immunoprecipitation revealed heterophilic interactions between claudin-3 and other claudin species in cell lines and in freshly excised human airway epithelium. Stable transfection, transepithelial resistance measurement, permeability coefficients, co-immunoprecipitation American journal of physiology. Lung cellular and molecular physiology Medium 12909588
2004 Disease-causing mutant WNK4 kinase binds and phosphorylates claudins 1-4 (including claudin-3) at tight junctions, with mutant WNK4 causing greater claudin phosphorylation than wild-type, and this is associated with increased paracellular chloride permeability in MDCK II cells. Stable expression in MDCK II cells, transepithelial ion permeability measurement, in vitro phosphorylation assay, co-immunoprecipitation Proceedings of the National Academy of Sciences of the United States of America High 15070779
2005 Claudin-3 expression in human ovarian surface epithelial (HOSE) cells increases cell invasion, motility, and survival, and is associated with increased MMP-2 activity; siRNA-mediated knockdown of claudin-3 in ovarian cancer cell lines reduces invasion. Stable transfection of HOSE cells, Boyden chamber invasion assay, wound-healing assay, siRNA knockdown, MMP-2 zymography Cancer research High 16103090
2007 The CLDN3 promoter contains a minimal Sp1-binding site critical for transcriptional activity; Sp1 binds preferentially to the unmethylated promoter, providing a mechanism for epigenetic silencing. siRNA knockdown of Sp1 significantly decreases CLDN3 mRNA and protein expression. Promoter deletion analysis, ChIP assay, in vitro DNA-binding assay, siRNA knockdown, DNA methylation analysis, histone acetylation ChIP Cancer biology & therapy Medium 17986852
2010 Claudin-3 acts as a general sealing component of the tight junction paracellular pathway: stable transfection of MDCK II cells with human claudin-3 elevated transepithelial resistance, decreased permeability to mono- and divalent cations, anions, and uncharged solutes (fluorescein, FD-4), and altered tight junction strand morphology toward uninterrupted meshwork loops, without affecting water permeability. Stable transfection of MDCK II cells, transepithelial resistance measurement, ion permeability assays, tracer flux assays, electron microscopy of tight junction strands Biochimica et biophysica acta High 20655293
2010 Derepression of CLDN3 in ovarian tumorigenesis correlates with loss of repressive histone modifications (H3K27me3 and H4K20me3) from its promoter. CLDN3 repression in normal ovarian epithelial cells is maintained by bivalent histone marks (H3K4me3 + H3K27me3), and DNA methylation is not required for CLDN3 repression in immortalized ovarian epithelial cells. ChIP assay for histone modifications, bisulfite sequencing, DNA methyltransferase and HDAC inhibitor treatments, quantitative RT-PCR Carcinogenesis Medium 20053926
2020 CLDN3 overexpression in human trophoblast HTR8/SVneo cells promotes proliferation, invasion, and migration while reducing apoptosis; this is associated with increased MMP-2 and MMP-9 expression and increased ERK1/2 phosphorylation, placing CLDN3 upstream of ERK1/2 signaling and MMP activation in trophoblasts. Lentiviral overexpression, CCK-8 assay, flow cytometry, Transwell assay, Western blot for ERK1/2 phosphorylation and MMP expression Experimental and therapeutic medicine Medium 32855729
2024 TET1 promotes CLDN3 transcription by demethylating the CLDN3 promoter region (-16 to +512 bp). PPM1G phosphatase catalyzes TET1 dephosphorylation, leading to TET1 protein destabilization, which impairs TET1-mediated CLDN3 promoter demethylation and suppresses epithelial-mesenchymal transition in cholangiocarcinoma cells. ChIP assay, bisulfite sequencing, phosphatase activity assay, co-immunoprecipitation, protein stability assays, EMT functional assays, pharmacological inhibitors Advanced science Medium 39477806
2025 HSF1 directly binds to the CLDN3 promoter and activates CLDN3 transcription in colorectal cancer cells, as demonstrated by ChIP assay; HSF1 knockdown reduces CLDN3 expression and inhibits CRC cell proliferation, migration, and invasion, while HSF1 overexpression promotes these behaviors. ChIP assay, Western blot, PCR, stable knockdown and overexpression, in vivo xenograft Neoplasma Medium 40162508
2026 CLDN3 directly interacts with TRIM28 as demonstrated by co-immunoprecipitation and immunofluorescence; TRIM28 mediates SUMOylation and degradation of CLDN3 protein, establishing TRIM28 as a writer controlling CLDN3 stability. CLDN3 knockdown in CRC cells decreases proliferation and migration, and CLDN3 overexpression reduces sensitivity to 5-FU. Co-immunoprecipitation, immunofluorescence, Western blot for SUMOylation, siRNA knockdown, overexpression, proliferation and migration assays IET systems biology Medium 41762617
2025 CLDN3 acts as a host antiviral defense protein against rotavirus (RV): the CLDN3 extracellular loop 1 (EC1) directly interacts with the N-terminal domain of RV outer capsid protein VP7, reducing viral adsorption. Structural analysis identified glutamic acid at position 74 (E74) of VP7 as critical for the CLDN3-VP7 interaction. Knockdown or knockout of CLDN3 promotes RV binding and entry, and the VP8* peptide of RV induces CLDN3 mislocalization from the plasma membrane as a counterdefense. The E74K mutation in VP7 disrupts the CLDN3-VP7 interaction and enhances viral pathogenicity in vivo. CLDN3 knockout/knockdown (RNAi, CRISPR), viral binding and entry assays, co-immunoprecipitation, structural studies, in vivo mouse infection model, site-directed mutagenesis (E74K) PLoS pathogens High 41860939
2025 In chick embryos, CLDN3 (expressed in non-neural ectoderm) is required for neural fold fusion in the spinal region. CLDN3 depletion decreases apical cell area at neural fold edges, increases phospho-MLC staining in the apical domain, and increases tissue tension in the non-neural ectoderm as measured by laser ablation. Treatment with the myosin II inhibitor blebbistatin partially rescues neural fold fusion defects, placing CLDN3 upstream of actomyosin contractility and apical cytoskeletal regulation. Morpholino knockdown in chick embryos, live imaging, cell segmentation analysis, laser ablation biomechanics, pMLC immunostaining, blebbistatin pharmacological rescue bioRxivpreprint Medium
2009 Claudin-3 contributes to tight junction strand formation and paracellular barrier regulation in intestinal epithelial context; downregulation of claudin-3 (along with claudins -4, -5, -7, -8, -12) is observed in intestinal inflammatory disorders, suggesting a role in maintaining epithelial barrier homeostasis. Expression analysis in intestinal inflammatory disease context (review/summary of experimental data) Genome biology Low 19706201
2025 ASCL2 physically interacts with CLDN3 as demonstrated by co-immunoprecipitation assay in breast cancer cells. Rescue experiments show that overexpression of CLDN3 can partly reverse the inhibitory effects of ASCL2 deletion on migration and invasion, indicating ASCL2 and CLDN3 act synergistically to promote malignant capacity of breast cancer cells. Co-immunoprecipitation, overexpression rescue experiments, proliferation/migration/invasion assays, xenograft tumor model Scientific reports Low 41318809

Source papers

Stage 0 corpus · 51 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2001 Multifunctional strands in tight junctions. Nature reviews. Molecular cell biology 2058 11283726
2005 A human protein-protein interaction network: a resource for annotating the proteome. Cell 1704 16169070
2019 Blood-Brain Barrier: From Physiology to Disease and Back. Physiological reviews 1645 30280653
2002 Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proceedings of the National Academy of Sciences of the United States of America 1479 12477932
1999 Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proceedings of the National Academy of Sciences of the United States of America 950 9892664
1999 Direct binding of three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH termini of claudins. The Journal of cell biology 921 10601346
2003 Tight junction proteins. Progress in biophysics and molecular biology 909 12475568
2021 Dual proteome-scale networks reveal cell-specific remodeling of the human interactome. Cell 705 33961781
2007 Structure and function of claudins. Biochimica et biophysica acta 666 18036336
2011 Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Briefings in bioinformatics 656 21873635
1999 Manner of interaction of heterogeneous claudin species within and between tight junction strands. The Journal of cell biology 588 10562289
2004 The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome research 438 15489334
2000 Tight junctions of the blood-brain barrier. Cellular and molecular neurobiology 403 10690502
2017 Intestinal epithelial claudins: expression and regulation in homeostasis and inflammation. Annals of the New York Academy of Sciences 343 28493289
2005 Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer research 318 16103090
2002 Claudin-based barrier in simple and stratified cellular sheets. Current opinion in cell biology 299 12231346
2009 The claudins. Genome biology 293 19706201
2006 The phenotypes of pluripotent human hepatic progenitors. Stem cells (Dayton, Ohio) 263 16627685
2003 Role of claudin interactions in airway tight junctional permeability. American journal of physiology. Lung cellular and molecular physiology 247 12909588
1997 Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo. The Journal of biological chemistry 223 9334247
2005 Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast cancer research : BCR 214 15743508
2004 Disease-causing mutant WNK4 increases paracellular chloride permeability and phosphorylates claudins. Proceedings of the National Academy of Sciences of the United States of America 213 15070779
2009 A genome-wide short hairpin RNA screening of jurkat T-cells for human proteins contributing to productive HIV-1 replication. The Journal of biological chemistry 211 19460752
2010 Claudin-3 acts as a sealing component of the tight junction for ions of either charge and uncharged solutes. Biochimica et biophysica acta 203 20655293
2001 Claudin promotes activation of pro-matrix metalloproteinase-2 mediated by membrane-type matrix metalloproteinases. The Journal of biological chemistry 192 11382769
2003 The DNA sequence of human chromosome 7. Nature 188 12853948
2001 Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer research 188 11691807
2001 The roles of claudin superfamily proteins in paracellular transport. Traffic (Copenhagen, Denmark) 187 11247307
2019 Tight junction proteins at the blood-brain barrier: far more than claudin-5. Cellular and molecular life sciences : CMLS 186 30734065
2003 CLDN23 gene, frequently down-regulated in intestinal-type gastric cancer, is a novel member of CLAUDIN gene family. International journal of molecular medicine 181 12736707
2010 Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications. Carcinogenesis 65 20053926
2007 Regulation of the CLDN3 gene in ovarian cancer cells. Cancer biology & therapy 55 17986852
2006 p16, MGMT, RARbeta2, CLDN3, CRBP and MT1G gene methylation in esophageal squamous cell carcinoma and its precursor lesions. Oncology reports 45 16685400
2012 Recombinant protein rVP1 upregulates BECN1-independent autophagy, MAPK1/3 phosphorylation and MMP9 activity via WIPI1/WIPI2 to promote macrophage migration. Autophagy 38 23051912
1998 Genes for the CPE receptor (CPETR1) and the human homolog of RVP1 (CPETR2) are localized within the Williams-Beuren syndrome deletion. Genomics 37 9878248
2025 Development of a bispecific antibody-drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors. Experimental hematology & oncology 7 40057807
2024 PPM1G Inhibits Epithelial-Mesenchymal Transition in Cholangiocarcinoma by Catalyzing TET1 Dephosphorylation for Destabilization to Impair Its Targeted Demethylation of the CLDN3 Promoter. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 5 39477806
2020 CLDN3 expression and function in pregnancy-induced hypertension. Experimental and therapeutic medicine 5 32855729
2023 Cloning and Molecular Characterization of the Recombinant CVB4E2 Immunogenic Viral Protein (rVP1), as a Potential Subunit Protein for Vaccine and Immunodiagnostic Reagent Candidate. Microorganisms 4 37317166
2022 DPP10-AS1-Mediated Downregulation of MicroRNA-324-3p Is Conducive to the Malignancy of Pancreatic Cancer by Enhancing CLDN3 Expression. Pancreas 4 37078946
2021 [Hydrogen-rich water improves progressive sperm motility in rats by reducing oxidative stress and upregulating CLDN3 and SRD5A2 expressions]. Zhonghua nan ke xue = National journal of andrology 1 37454313
2013 CLDN3 expression and significance - breast carcinoma versus ovarian carcinoma. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 1 23529315
2010 [Target-specific cytotoxic activity of recombinant fusion toxin C-CPE-ETA' against CLDN-3,4-overexpressing ovarian cancer cells]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 1 21223796
2026 Testicular Gap (CX43) and Tight Junction (OCLN, CLDN3, 5 and 11) Components in the Dog Are Affected by GnRH-Mediated Downregulation. Animals : an open access journal from MDPI 0 41594443
2026 Pan-Cancer Analysis of CLDN3 and Its Contribution to 5-FU Resistance in Colorectal Cancer. IET systems biology 0 41762617
2026 CLDN3 inhibits rotavirus attachment by targeting residue 74 of VP7. PLoS pathogens 0 41860939
2026 The Recombinant Viral Capsid Protein rVP1 Induces Protective Immunity Against Coxsackievirus B3 (CVB3) Lethal Challenges in Balb/c Mouse Model. Vaccines 0 41893781
2025 Elevated expression of HSF1 promotes the progression of colorectal cancer by activating CLDN3 transcription. Neoplasma 0 40162508
2025 CD44 and CLDN3 as immune-metabolic regulators in acute pancreatitis: a multi-modal transcriptomics study and experimental validation. Frontiers in immunology 0 41200201
2025 ASCL2 contributes to clinical assessments of breast cancer and mediates tumor progression via the interaction with CLDN3. Scientific reports 0 41318809
2025 Whole-exome sequencing in children with dyslexia implicates rare variants in CLDN3 and ion channel genes. Human genetics 0 41442065